Haemonetics (HAE) PT Lowered to $108 at Needham & Company; 'CSL Loss a Gut Punch But Not a Knock-Out'

April 19, 2021 12:06 PM EDT
Get Alerts HAE Hot Sheet
Price: $61.04 -0.65%

Rating Summary:
    5 Buy, 10 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $108.00 (from $158.00) while maintaining a Buy rating after the company announced that CSL Plasma will not renew its supply agreement for the use of the PCS2 Plasma Collection System which expires on 6/30/22.

"In FY20, the agreement accounted for $117M or ~12% of HAE's revenue with a gross margin similar to the company average," Matson commented. "We have lowered our estimates to reflect this news and a slower than expected recovery in the plasma market. We maintain our Buy rating since we see potential for upside from the adoption of NexSys and Persona by HAE's other customers to partially offset the impact of the loss of CSL in the US and given the steep decline in HAE's share price."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Needham & Company